XML 45 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Income (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Net sales $ 498,697 $ 516,514 $ 1,495,396 $ 1,523,291
Cost of goods sold 225,187 220,338 655,404 656,368
Gross profit 273,510 296,176 839,992 866,923
Selling, general and administrative expense 160,274 176,867 493,823 521,370
Research and development expense 49,004 45,387 154,263 136,327
Segment profit (loss) 64,232 73,922 191,906 209,226
Interest expense 11,901 12,341 37,498 41,148
Foreign exchange losses, net 448 6,346 3,508 12,132
Other (income) expense, net (1,511) (538) (14,692) (5,907)
Income before income taxes 53,394 55,773 165,592 161,853
Provision for income taxes (11,023) (9,911) (43,712) (43,031)
Net income including noncontrolling interests 42,371 45,862 121,880 118,822
Net loss (income) attributable to noncontrolling interests 13 35 (148) 162
Net income attributable to Bio-Rad $ 42,384 $ 45,897 $ 121,732 $ 118,984
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 1.50 $ 1.63 $ 4.31 $ 4.25
Weighted average common shares - basic 28,312 28,072 28,255 27,997
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 1.48 $ 1.61 $ 4.26 $ 4.18
Weighted average common shares - diluted 28,645 28,456 28,609 28,454